Enovis (ENOV) Cash from Financing Activities (2010 - 2026)
Enovis' (ENOV) quarterly Cash from Financing Activities came in at $26.0 million in Q2 2026, down 49.16% year-on-year from $51.2 million in Q2 2025, and up 135.69% on a QoQ basis from -$72.9 million in Q4 2025.
Enovis (ENOV) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Enovis (ENOV) has 17 years of Cash from Financing Activities data on file, last reported at $26.0 million in Q2 2026.
- On a quarterly basis, Cash from Financing Activities fell 49.16% year-over-year to $26.0 million in Q2 2026; TTM through Apr 2026 was -$77.6 million, a 331.74% decrease from a year earlier, with the FY2025 full-year figure at -$52.4 million, down 106.19% from the prior year.
- Cash from Financing Activities for Q2 2026 stood at $26.0 million, up from -$72.9 million in the prior quarter.
- Over the last five years, Cash from Financing Activities for ENOV reached as high as $864.5 million in Q1 2024 and fell as low as -$495.5 million in Q3 2022.
- Historically, Cash from Financing Activities has averaged $28.4 million across 5 years, with a median of $2.5 million in 2024.
- Across the five-year window, Cash from Financing Activities soared 3429.02% in 2024 and plunged 24837.16% in 2025, its largest moves.
- Year by year, Cash from Financing Activities stood at $41.6 million in 2022, then sank by 93.3% to $2.8 million in 2023, then sank by 819.97% to -$20.1 million in 2024, then tumbled by 263.12% to -$72.9 million in 2025, then surged by 135.69% to $26.0 million in 2026.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were $26.0 million in Q2 2026, -$72.9 million in Q4 2025, and -$36.9 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -25.00 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -26.93 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Enovis | 1.50 Bn | 1.47 Bn | 365.49 Mn | 26.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 26.02 Mn |
| Apr 3, 2026 | 26.02 Mn |
| Dec 31, 2025 | -72.92 Mn |
| Dec 31, 2025 | -72.92 Mn |
| Oct 3, 2025 | -36.91 Mn |
| Oct 3, 2025 | -36.91 Mn |
| Jul 4, 2025 | 6.23 Mn |
| Jul 4, 2025 | 6.23 Mn |
| Apr 4, 2025 | 51.19 Mn |
| Apr 4, 2025 | 51.19 Mn |
| Dec 31, 2024 | -20.08 Mn |
| Dec 31, 2024 | -20.08 Mn |
| Sep 27, 2024 | -148,000.00 |
| Sep 27, 2024 | -148,000.00 |
| Jun 28, 2024 | 2.51 Mn |
| Jun 28, 2024 | 2.51 Mn |
| Mar 29, 2024 | 864.54 Mn |
| Mar 29, 2024 | 864.54 Mn |
| Dec 31, 2023 | 2.79 Mn |
| Dec 31, 2023 | 2.79 Mn |